Validation of FDG-PET Segmentation Tools for Tumor Delineation by Correlation of CT- and FDG-PET Volume Measurements With Histopathology of Nodal Metastases of Head and Neck Carcinomas.

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT00782691

Enrollment

Registered

2008-10-31

Start date

2008-07-31

Completion date

Unknown

Last updated

2008-10-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Head and Neck Cancer

Keywords

FDG-PET segmentation tools, Head-and-neck cancer, Histological validation

Brief summary

Various methods of FDG-PET signal segmentation will be validated by correlation of histopathologically measured tumor dimensions in lymph node dissection specimens of head-and-neck cancer patients.

Interventions

OTHERCT-FDG/PET scan of the head-and-neck region

CT-FDG/PET scan of the head-and-neck region

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* All patients with N+ squamous cell carcinoma of the head and neck, planned for neck dissection. * Age \>18 years.

Exclusion criteria

* Pregnancy. * Women breast feeding

Design outcomes

Primary

Measure	Time frame
How accurate are the various FDG-PET segmentation tools?	Measurements are performed in conjunction with the clinical pathologist directly postoperatively.

Countries

Netherlands

Contacts

Primary ContactDominic A.X. Schinagl, MD

d.schinagl@rther.umcn.nlNL24-3614515

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026